Camrelizumab vs Placebo With Chemotherapy as Neoadjuvant Treatment in Triple-Negative Breast Cancer
Healthy DialogueShow Notes
Triple-negative breast cancer accounts for around 15% of breast cancers. Zhi-Ming Shao, MD, of Fudon University, joins JAMA Oncology Editor in Chief and JAMA Deputy Editor Nora Disis, MD, to discuss "Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients with Early or Locally Advanced Triple-Negative Breast Cancer: The CamRelief Randomized Clinical Trial."
Related Content: Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer
More from Healthy Dialogue
Breast cancer has undergone a dramatic transformation over the past several decades. Five-year survival rates are now 92% compared with 76% in 1975. In this special 2-part episode of Healthy Dialogue, Nancy E. Davidson, MD, oncologist and chief academic officer and executive vice president of Fred Hutchinson Cancer Center, discusses the advancements that led to these improvements.
Approximately 1 in 5 Americans live in rural areas, and in the coming years they will see dramatic shifts in their health care options due to the One Big Beautiful Bill Act. In this episode of Healthy Dialogue Mark Holmes, PhD, joins host Derek C. Angus, MD, MPH, to explore the impact of upcoming cuts to Medicaid and the $50 billion Rural Health Transformation Program.
Long COVID is a debilitating condition impacting millions of people around the world, but is still poorly understood, poorly defined, and poorly treated. In this episode of Healthy Dialogue, host Derek C. Angus, MD, MPH, discusses long COVID with Wes Ely, MD, MPH, professor of medicine at Vanderbilt University, and co-author of the NASEM report on Long COVID.
Medicaid provides health insurance for 1 in 5 Americans and plays a crucial role in US health care infrastructure. The One Big Beautiful Bill Act (OBBBA) is estimated to cut Medicaid spending by nearly $1 trillion by 2034 and cause millions of enrollees to lose coverage. In this episode of Healthy Dialogue, Julie Donohue, PhD, professor and chair of health policy and management at the University of Pittsburgh, breaks down what Medicaid is, who it covers, and how proposed cuts in the OBBBA could have far-reaching effects on patients, clinicians, hospitals and communities.
GLP-1 receptor agonists are one of the most revolutionary new classes of drugs in decades. In this episode of Healthy Dialogue, host Derek C. Angus, MD, MPH, sat down with Jens Juul Holst, MD, DMSc, and Lotte Bjerre Knudsen, DMSc, 2 pioneering scientists behind the discovery and development of GLP-1 RAs. Together, they traced the fascinating origin story of GLP-1 RAs and offered their thoughts on what comes next.